MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07075471

Acronym

MOVE

Enrollment

100

Registered

2025-07-20

Start date

2025-09-03

Completion date

2027-09-01

Last updated

2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tenosynovial Giant Cell Tumor

Brief summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Diagnosis of TGCT according to medical records 2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated. 3. Has provided informed consent and medical records release

Exclusion criteria

1\. Participant is active in an interventional clinical trial of vimseltinib

Design outcomes

Primary

Measure	Time frame
Duration of Vimseltinib Treatment	Baseline up to 12 months
Time to Discontinuation of Vimseltinib	Baseline to Discontinuation (Estimated up to 12 months)

Countries

United States

Contacts

CONTACTClinical Team

clinicaltrials@deciphera.com888-724-3274

STUDY_DIRECTORClinical Team

Deciphera Pharmaceuticals, LLC

Outcome results